|
1) 日本癌治療学会, 編. In: 制吐薬適正使用ガイドライン2010年5月. 東京: 金原出版; 2010
|
|
|
|
|
2) イメンド®適正使用ガイド
|
|
|
|
|
|
3) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
|
|
|
|
|
|
4) Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 2009; 10: 115-24
|
|
|
|
|
5) 西條長宏. 最新医学. 2006年11月号 特集: 肺癌治療-将来展望
|
|
|
|
|
|
6) Tiseo M, Martelli O, Mancuso A, et al. Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma. Tumori. 2007; 93: 138-44
|
|
|
|
|
|
7) Bodnar L, Wcislo G, Gasowska-Bodnar A, et al. Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomized phase II study. Eur J Cancer. 2008; 44: 2608-14
|
|
|
|
|
|
8) Willox JC, McAllister EJ, Sangster G, et al. Effects of magnesium supplementation in testicular cancer patients receiving cisplatin: a randomized trial. Br J Cancer. 1986; 54: 19-23
|
|
|
|
|
|
9) Kalemkerian GP, Darwish B, Varterasian ML. Tumor lysis syndrome in small cell carcinoma and other solid tumors Am J Med. 1997; 103: 363-7
|
|
|
|
|
|
10) ラスリテック®適正使用ガイド
|
|
|
|
|
|
11) 国立がん研究センター内科レジデント, 編. In: がん診療レジデントマニュアル第5版. 東京: 医学書院; 2010
|
|
|
|
|
|
12) Gabrilove JL, Cleeland CS, Livingston RB, et al. Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. JCO. 2001; 19: 2875-82
|
|
|
|
|